Skip to content

Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension

Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02426177
Enrollment
98
Registered
2015-04-24
Start date
2015-05-31
Completion date
2016-12-31
Last updated
2015-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postnatal Hypertension

Keywords

postpartum hypertension, labetalol in postpartum hypertension, nifedipine in postpartum hypertension

Brief summary

To compare effectiveness of oral labetalol and oral nifedipine for management of postpartum hypertension.

Detailed description

A comparison of oral labetalol and oral nifedipine for management of postpartum hypertension. Which drug is more effective in lowering blood pressures in patient with postpartum hypertension.

Interventions

DRUGLabetalol

anti-hypertensive agents

DRUGNifedipine

calcium channel blocker ,for lowering blood pressure

Sponsors

Dow University of Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 48 Years
Healthy volunteers
Yes

Inclusion criteria

* all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity. * age group between 18-48. * after informed consent.

Exclusion criteria

* all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded. * conditions in which drugs labetalol and nifedipine is contraindicated.

Design outcomes

Primary

MeasureTime frameDescription
Blood Pressure less than 140/90 mm of hg24 hoursless than 140/90 mm of hg

Contacts

Primary Contactfariha javed, mbbs
farihajaved207@yahoo.com923009298708

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026